| |
n
|
1-year
|
3-year
|
5-year
|
10-year
|
p-value†
|
|---|
|
Age (in years)
| | | | | |
0.02†
|
|
≤ 53
|
88
|
73.8 (56)
|
55.9 (34)
|
44.9 (20)
|
37 (1)
| |
|
> 53
|
83
|
88.7 (65)
|
68.4 (31)
|
62.4 (19)
|
55.5 (2)
| |
|
Sex
| | | | | |
0.09
|
|
Female
|
71
|
77.8 (47)
|
55 (25)
|
47.2 (15)
|
39.5 (2)
| |
|
Male
|
100
|
83.2 (74)
|
67.5 (40)
|
57.2 (24)
|
48 (1)
| |
|
Race
| | | | | |
0.27
|
|
Caucasian
|
140
|
83 (102)
|
63.8 (54)
|
55.4 (33)
|
48.3 (3)
| |
|
non-Caucasian
|
31
|
72.1 (19)
|
54.7 (11)
|
42.2 (6)
|
21.1 (0)
| |
|
PTT
| | | | | |
< 0.001†
|
|
Carcinoma
|
87
|
94 (76)
|
77.4 (45)
|
65.4 (28)
|
59.1 (2)
| |
|
Sarcoma
|
84
|
67.2 (45)
|
44.5 (20)
|
39.7 (11)
|
28.3 (1)
| |
|
DFI-1
| | | | | |
0.79
|
|
< 1 years
|
34
|
84.9 (22)
|
58.2 (10)
|
58.2 (10)
|
58.2 (1)
| |
|
1 to 5 years
|
92
|
76.3 (62)
|
63 (37)
|
52.8 (20)
|
42.7 (1)
| |
|
> 5 years
|
45
|
88.4 (37)
|
62.8 (18)
|
49.4 (9)
|
35.1 (1)
| |
|
Laterality
| | | | | |
0.03†
|
|
Unilateral
|
124
|
85.1 (96)
|
65.8 (51)
|
59.8 (31)
|
47.6 (1)
| |
|
Bilateral
|
47
|
69.3 (25)
|
51.2 (14)
|
34.9 (8)
|
34.9 (2)
| |
|
Magnitude
| | | | | |
0.02†
|
|
Wedge
|
118
|
77.9 (80)
|
55.8 (42)
|
46.1 (28)
|
40 (2)
| |
|
All other
|
53
|
87.9 (41)
|
76.7 (23)
|
76.7 (11)
|
54.8 (1)
| |
|
Number of lesions
| | | | | |
0.05
|
|
Single
|
48
|
91.4 (40)
|
69.3 (23)
|
62.7 (16)
|
51.2 (0)
| |
|
2–5
|
94
|
77.9 (65)
|
64.6 (34)
|
55.6 (19)
|
47.3 (3)
| |
|
> 5
|
29
|
72.9 (16)
|
40.1 (8)
|
27.5 (4)
|
27.5 (0)
| |
|
Neoadjuvant
| | | | | |
0.63
|
|
No
|
99
|
78.4 (66)
|
62.2 (37)
|
51.6 (22)
|
41.3 (1)
| |
|
Yes
|
72
|
84.4 (55)
|
62.2 (28)
|
55 (17)
|
49.5 (2)
| |
|
Procedure
| | | | | |
0.27
|
|
OPEN
|
135
|
78.9 (92)
|
60.9 (55)
|
50.5 (33)
|
41.5 (3)
| |
|
VATS
|
36
|
88.5 (29)
|
66.5 (10)
|
66.5 (6)
|
66.5 (0)
| |
- *All survival rates are expressed as % (number at risk), unless specified otherwise.
- † Two-tailed p-value < 0.05 considered statistically significant.
